Use of Perampanel and a Ketogenic Diet in Nonketotic Hyperglycinemia: A Case Report

Abstract

Background Nonketotic hyperglycinemia is a severe form of early onset epileptic encephalopathy caused by disturbances in the glycine cleavage system; the neurological damage is mainly attributed to overstimulation of the N-methyl-D-aspartate receptor.

Case The patient presented with a severe form of nonketotic hyperglycinemia and experienced frequent epileptic spasms and focal seizures, which were resistant to vigabatrin, adrenocorticotropic hormone therapy, and combined dextromethorphan and sodium benzoate treatments. By 9 months of age, perampanel reduced epileptic spasms by >50%. At 14 months of age, the ketogenic diet markedly reduced focal seizures and glycine levels in the cerebrospinal fluid.

Conclusion Perampanel reduced fast excitatory neuronal activity, which was induced by an α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor, followed by prolonged electrical depolarizations due to an N-methyl-D-aspartate receptor. Furthermore, the ketogenic diet may have modulated the excessive neurotoxic cascade through the N-methyl-D-aspartate receptor. Perampanel and ketogenic diet were effective for seizure control in our patient.

Keywords

nonketotic hyperglycinemia - NMDA receptor - perampanel - ketogenic diet - West's syndrome

Consent for Publication

Written consent was obtained from the patient's guardian for publication.

Publication History

Received: 09 September 2019

Accepted: 19 January 2020

Article published online:
16 March 2020

• References

• 1 Van Hove JLK, Coughlin II C, Swason M, Hennermann JB. GeneReviews. Seattle, WA: University of Washington, Seattle; 1993. –2019
• 2 Hamosh A, Maher JF, Bellus GA, Rasmussen SA, Johnston MV. Long-term use of high-dose benzoate and dextromethorphan for the treatment of nonketotic hyperglycinemia. J Pediatr 1998; 132 (04) 709-713
• 3 Chien YH, Hsu CC, Huang A. et al. Poor outcome for neonatal-type nonketotic hyperglycinemia treated with high-dose sodium benzoate and dextromethorphan. J Child Neurol 2004; 19 (01) 39-42
• 4 Swanson MA, Coughlin Jr CR, Scharer GH. et al. Biochemical and molecular predictors for prognosis in nonketotic hyperglycinemia. Ann Neurol 2015; 78 (04) 606-618
• 5 Scriver CR, Beaudet AL, Sly WS. et al. The Metabolic & Molecular Bases of Inherited Disease. 8th ed. New York, NY:: McGraw-Hill Medical Publishing Division; 2001
• 6 Dupuis N, Enderlin J, Thomas J. et al. Anti-ictogenic and antiepileptogenic properties of perampanel in mature and immature rats. Epilepsia 2017; 58 (11) 1985-1992
• 7 Cusmai R, Martinelli D, Moavero R. et al. Ketogenic diet in early myoclonic encephalopathy due to non ketotic hyperglycinemia. Eur J Paediatr Neurol 2012; 16 (05) 509-513
• 8 Kava MP, Robertson A, Greed L, Balasubramaniam S. Ketogenic diet, a potentially valuable option for the management of refractory epilepsy in classical neonatal nonketotic hyperglycinaemia: a case report. Eur J Clin Nutr 2019; 73 (06) 961-965
• 9 Donevan SD, White HS, Anderson GD, Rho JM. Voltage-dependent block of N-methyl-D-aspartate receptors by the novel anticonvulsant dibenzylamine, a bioactive constituent of L-(+)-beta-hydroxybutyrate. Epilepsia 2003; 44 (10) 1274-1279
• 10 Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia 2007; 48 (01) 43-58
• 11 Busanello EN, Moura AP, Viegas CM. et al. Neurochemical evidence that glycine induces bioenergetical dysfunction. Neurochem Int 2010; 56 (08) 948-954
• 12 Moura AP, Parmeggiani B, Gasparotto J. et al. Glycine administration alters MAPK signaling pathways and caused neuronal damage in rat brain: putative mechanisms involved in the neurological dysfunction in nonketoic hyperglycinaemia. Mol Neurobiol 2018; 55 (01) 741-750
• 13 Niu HX, Wang JZ, Wang DL. et al. The orally active noncompetitive AMPAR antagonist perampanel attenuates focal cerebral ischemia injury in rats. Cell Mol Neurobiol 2018; 38 (02) 459-466
• 14 Sato K. Why does hyperglycinemia exhibit so grave brain anomalies and so severe neurological symptoms?. J Theor Biol 2018; 455: 97-100
• 15 Bjoraker KJ, Swanson MA, Coughlin II CR. et al. Neurodevelopmental outcome and treatment efficacy of benzoate and dextromethorphan in siblings with attenuated nonketotic hyperglycinaemia. J Pediatr 2016; 170: 234-239